We examined the possibility that DDX3 expression could be correlated with KRAS, β-catenin and ZEB1 expression in tumors and their expressions could be associated with clinical outcomes in colorectal cancer patients, 145 tumors were enrolled to evaluate DDX3, KRAS, β-catenin, and ZEB1 expression by IHC. The gene discussed is KRAS; the disease is colorectal cancer.